GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (NAS:IMCR) » Definitions » EV-to-EBITDA

Immunocore Holdings (Immunocore Holdings) EV-to-EBITDA : -37.48 (As of May. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Immunocore Holdings's enterprise value is $2,427.2 Mil. Immunocore Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-64.8 Mil. Therefore, Immunocore Holdings's EV-to-EBITDA for today is -37.48.

The historical rank and industry rank for Immunocore Holdings's EV-to-EBITDA or its related term are showing as below:

IMCR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -72.88   Med: -15.6   Max: -2.84
Current: -37.61

During the past 6 years, the highest EV-to-EBITDA of Immunocore Holdings was -2.84. The lowest was -72.88. And the median was -15.60.

IMCR's EV-to-EBITDA is ranked worse than
100% of 462 companies
in the Biotechnology industry
Industry Median: 9.49 vs IMCR: -37.61

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Immunocore Holdings's stock price is $58.95. Immunocore Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.425. Therefore, Immunocore Holdings's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Immunocore Holdings EV-to-EBITDA Historical Data

The historical data trend for Immunocore Holdings's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunocore Holdings EV-to-EBITDA Chart

Immunocore Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - - -5.62 -62.89 -43.65

Immunocore Holdings Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -62.89 -56.73 -58.76 -47.48 -43.65

Competitive Comparison of Immunocore Holdings's EV-to-EBITDA

For the Biotechnology subindustry, Immunocore Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunocore Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunocore Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Immunocore Holdings's EV-to-EBITDA falls into.



Immunocore Holdings EV-to-EBITDA Calculation

Immunocore Holdings's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=2427.171/-64.765
=-37.48

Immunocore Holdings's current Enterprise Value is $2,427.2 Mil.
Immunocore Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-64.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunocore Holdings  (NAS:IMCR) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Immunocore Holdings's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=58.95/-1.425
=At Loss

Immunocore Holdings's share price for today is $58.95.
Immunocore Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.425.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Immunocore Holdings EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Immunocore Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunocore Holdings (Immunocore Holdings) Business Description

Traded in Other Exchanges
Address
92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.